On Demand Webinar: Optimising and managing the treatment of ALK+ aNSCLC - A Takeda Organised Event

This webinar features presentations by Yvonne Summers and Delyth McEntee
AKL+ aNSCLC Webinar

This webinar is for healthcare professionals only.

Prescribing information and adverse event reporting for ALUNBRIG ▼ (brigatinib), click here.


Yvonne SummersYvonne Summers

Delyth McEnteeDelyth McEntee

Sandra WakelinSandra Wakelin

As part of both Takeda UK’s and LCNUK’s commitment to high quality medical education for the lung cancer nursing community, we are delighted to present the first in Takeda's series of 'let's tALK' promotional meetings, supported by LCNUK. The let’s tALK meeting series is an educational initiative committed to delivering topical, timely and high quality medical education to healthcare professionals specialising in the management and treatment of lung cancer. We are delighted to present the first recording in our series entitled ‘Optimising and managing the treatment of ALK+ aNSCLC’. The session was presented by Dr Yvonne Summers (Consultant Medical Oncologist) and Delyth McEntee (Clinical Nurse Specialist) both from The Christie NHS Foundation Trust, and it addressed the evolving landscape of treatment options in ALK+ disease, as well as the practical challenges involved in managing ALK patients on treatment.

Takeda UK, supported by LCNUK

  • This promotional meeting was organised and funded by Takeda UK Ltd. and is for UK and Ireland healthcare professionals only.
  • This meeting was supported by LCNUK.
  • Takeda medicines were discussed during the meeting.

C-APROM/UKI/ALUN/0020 Date of preparation: February 2021

Published on: 
Tuesday, 2 March, 2021 - 09:00
Resource Type: 
Display priority: 

Thank you to our webinar organiser Takeda Oncology

TakedaAt TAKEDA ONCOLOGY, we endeavour to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients.

This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the resources of a global pharmaceutical company, we are finding innovative ways to improve the treatment of cancer.

We’ve built a portfolio of paradigm changing therapies and a leading oncology pipeline. Though we’ve made great strides in our fight against cancer, we are determined to do more – to work harder and to reach higher. We continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the innovators in oncology that we are today.

We know that our mission is not a quick or simple one, but we are up for the task: we aspire to cure cancer.


Join Lung Cancer Nursing UK

Be a member of a dynamic and cohesive forum of lung cancer nurse specialists (LCNS) working throughout the UK. Membership costs just £30 per year and is open to any specialist nurse who spends more than 50% of their working week or clinical activities in caring for patients with lung cancer.

Join Now

LCNUK Webinar Series

Our series of webinars will be continuing throughout 2021.

We hope you can join us on online.

Register for Upcoming Webinars